TriSalus Life Sciences
TLSI
9 hedge funds and large institutions have $17.3M invested in TriSalus Life Sciences in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 64 closing their positions.
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
86.76% less ownership
Funds ownership: 93.64% → 6.88% (-87%)
88% less funds holding
Funds holding: 72 → 9 (-63)
93% less capital invested
Capital invested by funds: $232M → $17.3M (-$215M)
98% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 64
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$124K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$20.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$27.1M |
| 2 |
DM
Deerfield Management
New York
|
-$9.93M |
| 3 |
GCL
Glazer Capital LLC
New York
|
-$9.56M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$7.9M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$7.78M |
TLSI Hedge Fund Activity: Q4 2022 in Review
9 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q4 2022, worth a combined $17.3M — down 93% from $232M a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of TLSI and 1 opened new positions — a net loss of 63 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $124K. The largest seller was BlackRock, exiting entirely with an estimated $27.1M sold.
- 9 institutional investors held TriSalus Life Sciences (TLSI) as of Q4 2022, down from 72 in Q3 2022.
- Funds reported $17.3M of TriSalus Life Sciences stock for Q4 2022, down 93% quarter-over-quarter.
- 1 fund opened new TriSalus Life Sciences positions in Q4 2022 and 64 closed out, a net change of -63 holders.
- The largest TriSalus Life Sciences buyer in Q4 2022 was Virtu Financial, an estimated $124K added.
- The largest TriSalus Life Sciences seller in Q4 2022 was BlackRock, an estimated $27.1M sold.
Based on aggregated 13F filings for Q4 2022.